MODERN STRATEGIES TO REDUCE NON-RELAPSE MORTALITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE MODERN ERA: IMPROVING DONOR SELECTION AND PATIENT SELECTION